Method for treating craniocerebral trauma

FIELD: medicine, neurology, traumatology, neurosurgery.

SUBSTANCE: the present innovation deals with treating acute craniocerebral traumas (CCT). Since the first hours of therapy it is necessary to perform intravenous drop injection of 2-ethyl-6-methyl-3-hydroxypyridine succinate per 200 mg twice daily in case of severe degree of disease and per 200 mg once daily in case of average and light degrees of the trauma. The method provides detoxication effect in acute period of CCT due to recently established antitoxic action of the preparation suggested , that is accelerated degradation and withdrawal of toxic metabolites out of cerebrospinal liquid.

EFFECT: higher efficiency of therapy.

3 ex, 3 tbl


The present invention relates to medicine, namely, neurology, traumatology, neurosurgery. It can be used in the treatment of acute traumatic brain injury.

Please note that oxitetraciclina succinate and 2-ethyl-6-methyl-3-hydroxypyridine succinate are one and the same substance. Both names priemlema, but we believe that the latter name is more appropriate (str radar 2004).

Traumatic brain injury is accompanied by the accumulation of cerebrospinal fluid (CSF) which are toxic to the Central nervous system of metabolites resulting from the degradation of brain tissue and hemorrhage in the subarachnoid space. With the advent of CSF medium molecular oligopeptides of oxygenated hemoglobin, bilirubin and serotonin bind violation of the tone of the cerebral vessels and cerebral ischemia. Thus, promising in the treatment of brain injury is detoxification CSF.

There is a method of treatment (I) acute traumatic brain injury, selected as a prototype, which includes the basic principles of evidence-based medicine, which consists in the correction of intracranial pressure, cerebral edema, prevention of seizures under dynamic observation neuroimaging methods. As treatment applied osmodiuretiki (mannitol, Resolume is), barbiturates (thiopental sodium, phenobarbital), corticosteroids (dexasone). This prototype also has disadvantages: long-term treatment, low efficiency, high cost of treatment, high risk of fatal outcome in acute degree (heavy stream) traumatic brain injury because it does not consider autointoxication brain toxic metabolites.

The invention solved the problem of reducing mortality, reducing the duration of treatment and time of hospitalization, improve patient outcomes while reducing cost.

This problem is solved by the fact that in acute severe traumatic brain injury from the first hours of treatment prescribed intravenous drip 200 mg 2-ethyl-6-methyl-3-hydroxypyridine succinate in saline solution, and frequency of administration depends on the severity. In heavy 2 times a day, with light and medium - 1 time per day.

The detailed implementation of the method. The method is based on the well-known fact increased antioxidant and lipoic action of the active substance 2-ethyl-6-methyl-3-hydroxypyridine succinate. The drug promotes the preservation of structural and functional organization of biomembranes, performance of transport of neurotransmitters and improve synaptic transmission. Is increased compensatory activation aerobes the glycolysis and decreased inhibition of oxidative processes in the Krebs cycle during hypoxia with an increase in the content of ATP and creatine phosphate, activation energosintezirutuyu of mitochondrial function, stabilization of cell membranes.

The authors it was experimentally proved toxic effect of the drug, which was manifested by accelerating disintegration of blood cells in CSF (mainly erythrocytes and their toxic metabolites: hemoglobin, oxyhemoglobin, hemosiderin). Also noted a more rapid elimination from CSF under the influence of the drug, which explains its antitoxic effect. Clinical effects of the drug 2-ethyl-6-methyl-3-hydroxypyridine succinate implemented, according to our data, by reducing the multifaceted manifestations of edema, ischemia, hypoxia, cephalalgia; patients quickly recovered the lost functions of the Central nervous system.

The method is performed in the following sequence. A patient with acute traumatic brain injury severe from the first hours of treatment prescribed 2-ethyl-6-methyl-3-hydroxypyridine succinate 200 mg in 200 ml of saline, intravenously 2 times a day. The drip is set in the morning and in the future, after 12 hours in the evening.

On the second or third day see a decrease in the degree of impairment of consciousness. Patient from a coma goes into the spoor. Continue treatment. 10 day fix the clarification of consciousness, reduction of meningeal and cerebral syndromes, smoothing the focal neurologic the tion of symptoms, reorganization of the CSF.

It was found that on the 20th day of treatment the patient begins to sit up in bed to go to the toilet with the accompanying, partly to maintain herself.

The patient in a state of moderate or mild severity of acute traumatic brain injury, prescribe intravenous drip 200 mg 2-ethyl-6-methyl-3-hydroxypyridine succinate 200 ml of saline 1 time per day.

On the second day, as a rule, mark the stabilization of consciousness of the patient. On average, on day 14 of treatment record almost complete disappearance of headaches. Restored cognitive function. The patient maintains itself. Under the supervision of a practitioner physical therapy leaves the chamber office on a walk.

Then the patient will be discharged to a rehabilitation center or at home with the implementation of outpatient treatment, including recommended further drug 2-ethyl-6-methyl-3-hydroxypyridine succinate.

In the case of severe and moderate acute craniocerebral trauma, the presence of residual corresponding to this description, repeat the treatment within 6 months to the steady improvement of the patient's condition.

Example 1. Sick And s M.P., 36 years. Diagnosis: gunshot wound of head fracture of the right parietal bone, brain contusion, lung-subarachnoid hemorrhage. Coma 1. On the background of the Russian Academy of Sciences the e conducted urgent therapy to the patient from the first hours of treatment prescribed 200 mg of 2-ethyl-6-methyl-3-hydroxypyridine succinate 200 ml fishriver intravenously 2 times a day.

Already at day 2, the patient was observed dynamics of full human consciousness: from coma 1 to light spoor. The patient opens the eyes of the challenge, can one word answer: “Yes”; “No”. Remains rough paresis of the left limbs.

On the 12th day from the beginning of treatment the patient has fully recovered. Clear consciousness. Decreased degree of paresis with 2 to 4 points. 21 days - sick in the mind and memory. Can sit with support. Sitting on the bed, can easily serve themselves. Remains mild depressive syndrome. However, there is interest in life, manifest positive emotions. After 2.5 months was discharged to a rehabilitation facility.

After 6 months the patient was recommended to undergo re-treatment with 2-ethyl-6-methyl-3-hydroxypyridine succinate on the proposed and previous methods. See the restoration of the lost functions. Psycho-emotional condition is satisfactory. Restored limited working capacity.

Example 2. Patient T s., 42. Diagnosis: acute closed craniocerebral injury, brain contusion. Massive subarachnoid hemorrhage. The spoor.

In hospital, diagnostic plan held an urgent lumbar puncture. Verified the diagnosis of subarachnoid hemorrhage. After therapy, conducted by emergency medical help is, from the first hours of treatment prescribed 200 mg of 2-ethyl-6-methyl-3-hydroxypyridine succinate 200 ml of physiologic saline intravenously, twice a day. On the second day note the decrease of the degree of impairment of consciousness from spoor to stun. Note the decrease meningeal and cerebral syndromes.

On the seventh day decreased the severity of paresis with 3 to 4 points. In the analysis of CSF noted a decrease in the number of erythrocytes with 14258 to 303 and osmolarity with 304 246.

Patient T s in consciousness, a moderate cephalalgia and easy meningeal syndrome.

On the 14th day - clear consciousness, remains mild hemiparesis to 4.5 points, can sit up in bed, simply to maintain itself.

After 1 month the patient is in satisfactory condition was discharged to a rehabilitation center. After six months, patients received rehabilitation treatment is proposed and investigated earlier method. Restored the ability to work, focal neurological symptoms no. There are moderate psychoemotional disorders.

Example 3. Patient M-VA., 49 years. Diagnosis: acute closed craniocerebral injury, brain injury of moderate severity.

Admitted to the hospital. The patient is prescribed 200 mg of 2-ethyl-6-methyl-3-hydroxypyridine succinate in saline solution intravenously 1 time per day.

On day 2 of treatment the patient was released from the spoor. N is observed a clear consciousness, but still lack of coordination (cerebellar symptoms and autonomic dysfunction. The patient spent 30 days in hospital and was discharged in satisfactory condition. Patient 4 months will re-treatment 2-ethyl-6-methyl-3-hydroxypyridine succinate previous method and rehabilitation.

Treatment outcomes observed that the patient recovered socio-psychological status. Working at your previous job. Further, the patient had not sought medical help for neurologists.

The effectiveness of the method

The method of using 2-ethyl-6-methyl-3-hydroxypyridine succinate in the first hours of treatment can effectively and quickly to stop the intoxication, which in turn reduces the degree of impairment of consciousness (on a scale Glazgo), reducing musculoskeletal disorders (on a scale NIH), and further the degree of disability (Barthel scale), the accelerated release of impairment of consciousness, and this allows a significant improvement in therapeutic process:

1. Reduced mortality in the treatment of acute severe traumatic brain injury;

2. Declining terms of rehabilitation of the CSF, which leads to a faster reduction of concomitant manifestations of brain injury (edema, ischemia, cephalalgia);

3. Reduced time of treatment of acute heavy, medium and light craniocerebral trauma;

4. Stand who agrees effectiveness of the treatment and reduces the cost of bed-days in hospital for patients with acute traumatic brain injury.

Table 1.

Treatment of acute severe traumatic brain injury. Hospital.
Methods of treatment of acute head injuryThe number of patientsMortalityThe treatment timeThere are residual effects (in % from number of patients treated) %
Prototype method1488659%2.5 months.93%
The proposed method1565334%2,0 months.87%

Conclusions: in the treatment by the proposed method reduced mortality, reduced treatment time, less pronounced observation residual phenomena (Table 1).

Table 2.

The dynamics of rehabilitation of cerebral spinal fluid (CSF) in patients with acute severe head injury
The timing of lumbar puncture1-2 days6-8 days
TreatmentThe number of patientsErythrocytes OsmolarityErythrocytesOsmolarity %
Prototype method (traditional treatment)8216342±6300100302±16,31009417±22357,6297±12,298,3
The proposed method (using drug) on the background of traditional treatment9114342±4951100304±17,21007295±116,050,86248± and 11.381,57

Table 2 shows that with the proposed method using 2-ethyl-6-methyl-3-hydroxypyridine succinate on the background of traditional treatment there has been a more rapid resorption of red blood cells, and consequently, hemoglobin, oxyhemoglobin, hemosiderin, which are toxic for CSF. The decrease in the osmolarity and the accelerated disintegration of blood cells in the CSF is manifested in the clinic in the form of reduction of edema, ischemia, cephalgia.

Conclusions: in the treatment by the proposed method is observed more rapid and effective rehabilitation of the CSF, which leads to b is more rapid restoration of the lost functions of the Central nervous system.

Table 3.

Treatment of acute medium and light craniocerebral injuries.
TreatmentThe number of patientsThe incoordinationNeurosis-like disordersAutonomic disordersThe treatment time % 
Prototype method655585%5787%4772%4 weeks
The proposed method483981%3063%3165%3 weeks

Conclusions: the treatment by the proposed method is more efficient, less long-term time and less costly (table 3).


1. Pathogenesis, diagnosis and treatment of traumatic brain injury and its consequences./Antonopoulou, Lubriderm, A.a.potapov etc. //Ukr. The matters. Neurosurgery them. Burdenko. - 1994. No. 4. - P.18-25.

2. Butakov S.M. Vascular and tissue changes in contusion foci of brain in acute PE is the iodine traumatic brain injury with varying degrees of impaired consciousness. // 's lives.-the honey. expertise." 1993. - T.36. No. 2. - P.12-15.

3. Clinical guide. Volume II, Chapter 7 /Under the editorship of Academician A.N. Konovalov, Professor Lublijana, ATV): the Antidoron, 2001.

The method of treatment of acute traumatic brain injury), characterized in that the first hours of treatment intravenous drip 2-ethyl-6-methyl-3-hydroxypyridine succinate dose of 200 mg 2 times per day with severe and 1 time per day 200 mg for moderate and mild injuries.


Same patents:

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with peroral liquid compositions which could be designed into gelatinous capsules. The suggested pharmaceutical composition includes a pharmaceutically active agent, a solubilizing agent and, not obligatory, a surface-active substance and a plastifying agent. The pharmaceutically active agent has got, at least, one acidic fragment, preferrably, that of carbonic acid being chosen out of the group of non steroid antiphlogistic preparations being acid-soluble at acid : dissolved substance ratio being from 3:1 to 10000:1. New compositions provide increased rates and degrees of absorption of pharmaceutically active agent and minimize side effects caused by such active substances.

EFFECT: higher efficiency of application.

42 cl, 39 ex

FIELD: organic chemistry, pharmaceutical compositions.

SUBSTANCE: invention relates to substituted 3-oxo-1,2,3,4-tetrahydroxinoxalines of general formula 1 , wherein R1 represents substituted sulfanyl or substituted sulfonyl group, containing as substituent optionally substituted C1-C4-alkyl, optionally substituted C3-C8-cycloalkyl, aryl-(C1-C4)alkyl optionally substituted in aril or alkyl group, heterocyclyl-(C1-C4)alkyl optionally substituted in heterocycle or alkyl group; R2 and R3 independently represent hydrogen, halogen, CN, NO2, optionally substituted hydroxyl, optionally substituted amino group, optionally substituted carboxylic group, optionally substituted carbamoyl group, optionally substituted arylcarbonyl group or optionally substituted heterocyclylcarbonyl group; R4 and R5 independently represent hydrogen or inert substituent. Claimed compounds are high effective kaspase-3 inhibitors and are useful in production of pharmaceutical compositions for treatment of diseases associated with excess apoptosis activation, as well as for experimental investigations of apoptosis in vivo and in vitro. Also disclosed are pharmaceutical composition in form of tablets, capsules or injections in pharmaceutically acceptable package, as well as method for production thereof and therapy method.

EFFECT: pharmaceutical composition for apoptosis treatment and investigation.

6 cl, 3 dwg, 8 ex, 1 tbl

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: in the suggested composition one should apply heptapeptide of Met-Glu-His-Phe-Pro-Gly-Pro sequence (heptapeptide A) for treating ischemic insult due to introducing 2 drops of compositions into each nasal canal 5-6 times daily for 10 d at disease of average severity degree, and in case of severe degree - per 3 drops of the present composition into each nasal canal 7 times daily for 10 d. The present innovation provides increased efficiency at decreased concentration of heptapeptide without any side effects.

EFFECT: higher efficiency of therapy.

2 cl, 6 dwg, 8 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: the suggested preparation is being cytidine diphosphate choline (CDP-choline) known previously as the preparation to restore cerebral phospholipid structure and for treating mammalians, people among them, subjected to the action of stimulants. Moreover, it is necessary to note that CDP-choline decreases the duration of abstinence symptoms (tremor, convulsions, weakness, emotional instability, nervousness, social reserve) and causes either the decrease or stoppage of alcohol intake.

EFFECT: higher efficiency of therapy.

5 cl, 5 ex

FIELD: medicine, organic chemistry.

SUBSTANCE: the present innovation deals with new benzothiazole derivatives and medicinal preparation containing these derivatives for treating diseases mediated by adenosine receptor A2.A.. The present innovation provides efficient treatment of the above-mentioned diseases.

EFFECT: higher efficiency of therapy.

14 cl, 354 ex

FIELD: animal science.

SUBSTANCE: the suggested biopreparation named "Lactobifadol" should be applied 1 mo before the impact of the mentioned stress factor at the dosage of 100-200 mg/kg body weight, daily. Application of "Lactobifadol" enables to normalize physiological body state and decrease the losses of meat production.

EFFECT: higher efficiency of prophylaxis.

1 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: means comprises amber acid and/or its salts, fructose, dry extraction of Saint John's wort, magnesium ion sources, potassium ion sources as active bases and auxiliary substances, carriers and/or fillers when needed.

EFFECT: enhanced effectiveness of treatment.

4 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves estimating vegetative tonus using cardiointervalography approach and its medication adjustment under cardiointervalography control. The cardiointervalography examination is carried out before applying treatment, in the course of and after the treatment. Each time vegetative tonus increment is estimated on the basis of voltage index. When applying medication adjustment, nootrop group preparations are used that are selected before applying treatment with initial vegetative tonus disorder distinguished by vagotonia or sympathicotonia being taken into account. Preparation or combination of preparations or their doses and application duration is adjusted on basis of vegetative status direction changes obtained from cardiointervalography examination data. The treatment is continued until vegetative status direction change stops towards normotonia.

EFFECT: enhanced effectiveness in selecting individual treatment course.

3 cl, 3 dwg

FIELD: pharmaceutical chemistry, in particular pharmaceutical compositions.

SUBSTANCE: new spyro(2H-1-benzopyrane-2,4'-piperidine) derivatives of general formula I

and pharmaceutically acceptable salts thereof are disclosed. In formula dotted line is optional bond; Y is 1-4 substituents independently selected from hydrogen, halogen, C1-C4-alkyl, optionally substituted with one or more halogen, C1-C6-alkyloxy, optionally substituted with halogen or C3-C6-cycloalkyl, C2-C6-alkenyloxy, C2-C6-alkinyloxy, C3-C6-cycloalkyloxy, C6-C12-aryloxy, arylalkyloxy, pyridilmethoxy, SR3, NR3R4, OSO2R5, and NR3SO2R4; or two Y together may form O-(CH2)n-O or O-(CF2)n-O, wherein n is 1 or 2: or Y is condensed C5-C6-aryl group; X is 1-3 substituents independently selected from hydrogen, halogen, hydroxyl, C1-C6-alkoxy, and C1-C4-alkyl; R1 is hydrogen, C1-C4-alkyl, or C6-C12-aryl; R2, R3, and R4 are independently hydrogen or C1-C4-alkyl; R5 is C6-C12-aryl. Also disclosed are pharmaceutical compositions including said derivatives and having activity in relation to CNS.

EFFECT: new compounds with valuable pharmacological action.

9 cl, 1 tbl, 83 ex

FIELD: medicine, obstetrics.

SUBSTANCE: the present innovation deals with three types of species of medicinal plants to prevent late gestoses in pregnant women out of high-risk group: for pregnant women in case of affected dream the suggested species contains flowers of camomile and calendula, leaves of Bergenia and balm, hops collective fruits, and dogrose fruits taken at a certain ratio; for pregnant women in case of chronic urinary infection and neurocirculatory dystonia it contains flowers of camomile and calendula, mountain ash and dogrose fruits, fruits and seeds of Schizandra, leaves of Bergenia and bearberry taken at a certain quantitative ratio; for pregnant women in case of thyroid dysfunction and affected metabolism it contains flowers of camomile and Filipendula, bearberry leaves, Bupleurum grass, fennel seeds, valerian rhizome and roots, hops collective fruits, fruits of black currant taken at a certain quantitative ratio. Species of medicinal plants efficiently prevents and treats at development of both early and late gestoses in pregnant women.

EFFECT: higher efficiency of prophylaxis and therapy.

3 cl, 3 ex

FIELD: medicine, intensive therapy.

SUBSTANCE: the present innovation deals with body detoxication due to introducing sodium hypochlorite at concentration of 75-90 mg/l at the volume of 400 ml at the rate of 70-80 drops/min. The present innovation enables to restore hemodynamics, normalize the level of thyroid hormones and the values of immunological status and decrease the values of lipid peroxidation due to applying less concentration of sodium hypochlorite that, in its turn, also, prevents the damage of peripheral veins.

EFFECT: higher efficiency.

4 ex, 4 tbl

Disinfectant // 2251416

FIELD: veterinary sanitation.

SUBSTANCE: in the suggested disinfectant one should dissolve electrochemically activated neutral anolyte, containing 0.6 mg/ml active chlorine, with running water at 1:5 ratio and the composition of diluted electrochemically activated neutral anolyte should be supplemented with 1-1.5 mg acetic acid per 1 ml preparation. The innovation enables to decrease the concentration of active chlorine and energy expenses at keeping initial high bactericidal activity of electrochemically activated neutral anolyte and, also, apply it in aerosol form for air sanitation in poultry-breeding housings when poultry is present.

EFFECT: higher efficiency of disinfection.

1 tbl

FIELD: medicine.

SUBSTANCE: means comprises amber acid and/or its salts, fructose, dry extraction of Saint John's wort, magnesium ion sources, potassium ion sources as active bases and auxiliary substances, carriers and/or fillers when needed.

EFFECT: enhanced effectiveness of treatment.

4 cl, 4 tbl

FIELD: experimental medicine.

SUBSTANCE: on should introduce solution into fracture area at the following ratio of ingredients, g/l: 1-hydroxyethylidenediphosphonic acid 1.80 - 2.06, water-free calcium chloride 1.44 - 2.22, gadolinium (III) nitrate hexahydrate 0.30 - 0.40, dysprosium (III) chloride hexahydrate 0.038 - 0.076, moreover, solution's pH corresponds to 7.3 - 7.8. The present innovation enables to shorten the process of bony tissue regeneration in the site of its lesion or defect and, also, shorten the period for restoring normal physiological function of traumatized bone.

EFFECT: higher efficiency of regeneration.

22 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves introducing cauterizing necrotizing composition like paste containing silver nitrate and dextrane into uterine cavity. Paste contact to target tissue is supported during time enough for reaching chemical necrosis. Then cauterizing composition is brought in contact with deactivating agent like aqueous solution of sodium chloride and removed from the uterine cavity later on. It is proposed to protect non-target tissue by supplying protection agent to it and carrying out previously described steps.

EFFECT: enhanced effectiveness of cauterization controlled in time and action intensity degree; avoided other tissue injuries.

30 cl, 8 dwg

FIELD: polymer materials in medicine.

SUBSTANCE: aqueous solution according to invention contains 0.05-0.11 mole/L oxalic acid and 0.02-0.17 mole/L alkali metal salt(s). Treatment of polymethylmethacrylate materials with such solution allows complete removal of residual monomer without alteration of molecular mass and supramolecular structure of polymer material.

EFFECT: reduced risk of rejection of implants and improved mechanical and optical properties thereof.

1 tbl, 3 ex

FIELD: animal science, veterinary science.

SUBSTANCE: the suggested composition for disinfecting objects of animal science includes dispersion dyestuff and active substance as conservant-disinfectant FH and, additionally, cationic surface active substance at certain quantitative ratios of components. Moreover, disinfecting composition contains either alkyldimethylbenzylammonium chloride, or cetylpiridinium chloride or hexidine chloride as cationic surface active substance. This innovation provides increased terms of residual biocidal (bactericidal and fungicidal) activity.

EFFECT: higher efficiency of disinfection.

1 cl, 11 ex

FIELD: animal science, veterinary science.

SUBSTANCE: the suggested composition includes either chalk or slaked lime, additionally, it may contain conservant-disinfectant FX at certain ratios of components. The innovation provides increased terms of residual biocidal (bactericidal and fungicidal) activity.

EFFECT: higher efficiency of disinfection.

8 ex

FIELD: medicine.

SUBSTANCE: method involves puncturing pyogenic abscess cavity under ultrasonic control with draining tube left therein. Laparoscope connected to monitor unit is introduced into abscess cavity. One of introduced drains is set in upper point of the cavity and the other one in lower point. The abscess cavity is filled with ozonized solution to 2/3 of its volume and bubbled with ozone-oxygen mixture during 2-3 min changing the solution until it becomes transparent. The emptied cavity walls are treated from distance of 3-4 cm with laminar airflow heated to 38-40°C under pressure of 1-1.5 atm during 2-3 min. Next to it, the cavity walls are irradiated from distance of 2-3 cm with non-coherent red light during 2-3 min per each area.

EFFECT: improved safety conditions and healing quality.

FIELD: medicine, pulmonology.

SUBSTANCE: one should perform lovage in three stages:during the 1st stage one should carry out lovage of tracheoalveolar tree for 3-4 min with 60-80 ml 0.08%-sodium hypochlorite solution, at the 2nd stage one should introduce 5-7 ml 10%-fluimucyl solution into tracheobronchial tree for 4-6 min, and at the 3d stage one should perform lovage of tracheobronchial tree for 3-4 min with 60-80 ml 0.11%-sodium hypochlorite solution. The present innovation favors secreta release of decreased viscosity into large bronchi that simplifies its evacuation and this, in its turn, simplifies the access of antiphlogistic and antibacterial preparations towards tracheobronchial tree's mucosa that leads to interrupting inflammatory process in more shortened terms.

EFFECT: more prolonged period of remission.

2 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to new 2-aminopyridine derivatives of formula I , wherein R1 is cyano, carboxyl or carbamoyl; R2 is hydrogen, hydroxyl, C1-C6-alkoxy or phenyl; R3 and R4 are aromatic hydrocarbon such as phenyl or naphthyl, 5-14-membered 5-14-membered optionally substituted aromatic group, excepted cases, when (1) R1 is cyano, R2 is hydrogen, and R3 and R4 are simultaneously phenyl;(2) R1 is cyano, R2 is hydrogen, R3 is 4-pyridyl, and R4 is 1-pyridyl; (3) R1 is cyano, R2 is 4-methylphenyl, and R3 and R4 are simultaneously phenyl;(4) R1 is cyano, R2, R3 and R4 are simultaneously phenyl, or salts thereof. Derivatives of present invention have adenosine receptor antagonist activity and are useful in medicine for treatment of irritable bowel syndrome, constipation, and defecation stimulation.

EFFECT: 2-aminopyridine derivatives as adenosine receptor antagonists useful in medicine.

34 cl, 2 tbl, 179 ex